Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma

References

• US Cancer Statistics Working Group. United States cancer statistics: 1999–2005 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available from: http://cdc.gov/uscs
   Google Scholar
• Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute; [Based on November 2008 SEER data submission, posted to the SEER website 2009.] Available from: http://seer.cancer.gov/csr/1975_2006
   Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology™ non-Hodgkin's lymphomas (Version 1.2010). © 2009 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org
   Google Scholar
• Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006;133:3–18.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Itälä M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37:367–372.
   PubMed Web of Science ®Google Scholar
• Swain S, Whaley F, Ewer M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879.
   PubMed Web of Science ®Google Scholar
• Rubex® [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2001.
   Google Scholar
• Hacker M, McKennon, Singer JW. Lack of iron binding by pixantrone is associated with reduced production of reactive oxygen species and myocyte cytotoxicity in vitro. Blood 2009;114(Suppl. 1): Abstract 4806.
   Google Scholar
• Cavaletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007;25:187–195.
   PubMed Web of Science ®Google Scholar
• Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 1979;63:1877–1883.
   PubMedGoogle Scholar
• Evison BJ, Chiu F, Pezzoni G, et al. Formaldehyde-activated pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 2008;74:184–194.
   PubMed Web of Science ®Google Scholar
• Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumorigenesis 2001;87:407–416.
   Google Scholar
• Pettengell R, Narayanan G, Mendoza FH, et al. Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27(Suppl.): Abstract 8523.
   Google Scholar
• Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003;88:888–894.
   PubMed Web of Science ®Google Scholar
• Fayad L, Liebmann J, Modiano M, et al. Preliminary results of a phase I/II trial of BBR–2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2004;104(Suppl. 1): Abstract 1324.
   Google Scholar
• Lim ST, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR 2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48:374–380.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
   Google Scholar
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471–2508.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0. [Published 30 April 1999.] Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
   Google Scholar
• National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. [Published 31 March 2003, revised 10 June 2003.] Available from: http://www.vumc.nl/afdelingen/hematologie/studiesstand/algemeen/2458653/
   Google Scholar
• Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Dawson L, Jodrell D, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353–2359.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661–667.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Jermann M, Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004;15:511–516.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009;27(Suppl.): Abstract 8509.
   Google Scholar